MESOBLAST SHOWCASED AT ASX PREMIER INVESTOR DAY EVENT New York, USA: November 15 and Melbourne, Australia: November 16, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at the Australian...
Mesoblast Showcased at ASX Investor Day
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Mesoblast Limited showcased its developments at the ASX Investor Day, highlighting its transformation into a commercial-stage biotechnology company. The presentation emphasized the growth of Ryoncil and the company's plans to expand its cellular therapy platform into various high-value indications. Mesoblast outlined its key priorities, including advancing rexlemestrocel-L for chronic low back pain and heart failure. The event provided insights into Mesoblast's strategic direction and ongoing commitment to developing innovative therapies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
In the deck
Story so far
Earlier from Mesoblast
- CEO Presentation ASX Investor Day
- Initial Director's Interest Notice
- Results of Meeting
- CEO Presentation to 2026 Annual General Meeting
- Mesoblast Chair Message to 2026 AGM
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast